ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population ( Dose-dependent effect for oral semaglutide was assessed and proven in Japanese PIONEER 9 trial, where greater reduction of HbA1c and weight loss was achieved with higher dose of oral semaglutide compared to placebo and 0.9 mg liraglutide ( Mechanisms related to cardiovascular effects of GLP-1 receptor agonists The cardiovascular effects of GLP-1 receptor agonists in CVOTs can be attributed to several mechanisms
Nutrients, 14 (19), 4019
Participants taking Mounjaro experienced an average A1C reduction of 2%, with many achieving A1C levels below 7%
PlexusDx offers multiple alternatives: slower dose escalation timelines, alternative formulations (Oral Semaglutide instead of injection), different medication classes (Tirzepatide), or specialized protocols like the Microdose GLP-1 Protocol ($129/mo) for gentler onset
Studies also show that tirzepatide can potentially decrease liver fat content due to its weight loss effects, possibly improving conditions like fatty liver disease
Insert the needle into the vial through the rubber stopper and push the air in
